<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094755</url>
  </required_header>
  <id_info>
    <org_study_id>D5130L00047/ISSBRIL0152</org_study_id>
    <nct_id>NCT02094755</nct_id>
  </id_info>
  <brief_title>Aspirin and Clopidogrel Reactivity in Patients With Critical Limb Ischemia (CLI)</brief_title>
  <official_title>Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb&#xD;
      loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a&#xD;
      major cause of death and disability (secondary to myocardial infarction, stroke and&#xD;
      amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years&#xD;
      respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin&#xD;
      and clopidogrel (previously referred to as &quot;resistance&quot;) is associated with an increased risk&#xD;
      of recurrent cardiovascular events after percutaneous coronary interventions and acute&#xD;
      coronary syndromes. The prevalence and significance of High on-treatment Platelet Reactivity&#xD;
      (HPR) in patients with critical limb ischemia treated with aspirin and/or clopidogrel is not&#xD;
      known.&#xD;
&#xD;
      The investigators project aims to investigate the prevalence of HPR (to aspirin and&#xD;
      clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at&#xD;
      University of Southern California (USC) affiliated hospitals (Los Angeles County Hospital and&#xD;
      Keck Hospital of University of Southern California).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective clinical study will investigate the prevalence of high on- treatment&#xD;
      platelet reactivity (HPR) in one hundred patients with critical limb ischemia (CLI), at the&#xD;
      Keck Hospital of USC and Los Angeles County Medical Center (LAC+USC). Platelet inhibition to&#xD;
      aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet&#xD;
      inhibition will be evaluated with two different tests: the vasodilator-stimulated&#xD;
      phosphoprotein (VASP) and the VerifyNow® purigenic receptor P2Y12 (VN-P2Y12) assays. All&#xD;
      platelet function analyses will be performed once after a minimum of one week of&#xD;
      uninterrupted dual antiplatelet therapy with aspirin and clopidogrel. High on-treatment&#xD;
      Platelet Reactivity on aspirin treatment (HPRA) group will be defined as aspirin reaction&#xD;
      units (ARU) ≥550 by the VerifyNow® ASA assay. High on-treatment Platelet Reactivity on&#xD;
      clopidogrel (HPRC) group will be defined as P2Y12 reaction units (PRU) ≥208 by the VerifyNow®&#xD;
      assay and Vasodilator-stimulated phosphoprotein-platelet reactivity index (VASP-PRI) ≥50% by&#xD;
      the vasodilator-stimulated phosphoprotein (VASP) assay. All other patients will be assigned&#xD;
      to the adequate platelet reactivity on therapy (APR) group. Prevalence of high on-treatment&#xD;
      platelet reactivity will then be calculated for aspirin and/or clopidogrel&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2013</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">November 21, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</measure>
    <time_frame>Single measurment after a minimum of one week of uninterrupted dual antiplatelet therapy with aspirin and clopidogrel</time_frame>
    <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Single cohort</arm_group_label>
    <description>Single cohort will receive Blood draw only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw only</intervention_name>
    <description>Blood draw only</description>
    <arm_group_label>Single cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Draw&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patient population will include one-hundred patients with a diagnosis of CLI. We will&#xD;
        only include in the study CLI patients who as part of their standard of care medical&#xD;
        treatment are receiving dual antiplatelet therapy with aspirin 81 mg and clopidogrel 75 mg&#xD;
        daily for at least one week.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  EXPERIMENTAL GROUP: Patients with a diagnosis of critical limb ischemia (CLI) and&#xD;
             uninterrupted treatment with aspirin and/or clopidogrel for at least one week before&#xD;
             testing.&#xD;
&#xD;
          -  CONTROL GROUP: 10 normal volunteers without any known co-morbidities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic use of nonsteroidal anti-inflammatory drugs, thrombocytopenia (platelet count&#xD;
             &lt;100 × 103/μl), use of an oral anticoagulant (warfarin), glycoprotein (GP) IIb/IIIa&#xD;
             inhibitors, or fibrinolytic drugs within 30 days before testing. Any documented&#xD;
             history of hypercoaguable states or history of medication non-compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Clavijo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>March 31, 2017</results_first_submitted>
  <results_first_submitted_qc>April 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Leonardo Clavijo</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine Director of Vascular Medicine &amp; Peripheral Interventions</investigator_title>
  </responsible_party>
  <keyword>ASA-PLAVIX Reactivity in CLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.&#xD;
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.&#xD;
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</title>
        <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
        <time_frame>Single measurment after a minimum of one week of uninterrupted dual antiplatelet therapy with aspirin and clopidogrel</time_frame>
        <population>High on-treatment platelet reactivity on clopidigrel (HPRC) was defined as VerifyNow®P2Y12 reactive units (PRU) &gt;208 and VASP-platelet reactivity index (VASP-PRI) &gt;50%.&#xD;
Thromboxane A2 (TXA2) inhibition was measured with the VerifyNow®aspirin test and High on-treatment reactivity on aspirin (HPRA) was defined as aspirin reaction units (ARU) &gt;550.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Cohort</title>
            <description>Patients were included who had a diagnosis of CLI and who received uninterrupted treatment with ASA and/or clopidogrel for ≥1 week prior to platelet inhibition testing.</description>
          </group>
        </group_list>
        <measure>
          <title>Asses the Prevalence of High On-treatment Platelet Reactivity in Critical Limb Ischemia Patients Treated With Aspirin and Clopidogrel.</title>
          <description>Platelet inhibition to aspirin will be evaluated with the VerifyNow® aspirin (ASA) test. Clopidogrel platelet inhibition will be evaluated with two different tests: the vasodilator-stimulated phosphoprotein (VASP) and the VerifyNow® purinergic receptor P2Y12 (VN-P2Y12) assays.</description>
          <population>High on-treatment platelet reactivity on clopidigrel (HPRC) was defined as VerifyNow®P2Y12 reactive units (PRU) &gt;208 and VASP-platelet reactivity index (VASP-PRI) &gt;50%.&#xD;
Thromboxane A2 (TXA2) inhibition was measured with the VerifyNow®aspirin test and High on-treatment reactivity on aspirin (HPRA) was defined as aspirin reaction units (ARU) &gt;550.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HPR on Clopidogrel</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HPR on Aspirin</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HPR on Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>API on Both</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Critical limb ischemia patients with clinical indication of aspirin and clopidogrel dual antiplatelet therapy with for at least 1 week as standard of care, were monitored for adverse events for the length of study participation which was 1 day from study enrollment to the last study intervention.</time_frame>
      <desc>In adherence to the clinical trials.gov adverse event and serious adverse event definitions</desc>
      <group_list>
        <group group_id="E1">
          <title>Single Cohort</title>
          <description>Single cohort will receive Blood draw only.&#xD;
Blood draw only: Blood draw only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Leonardo Clavijo</name_or_title>
      <organization>University of Southern California</organization>
      <phone>3234426130</phone>
      <email>lclavijo@usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

